Leerink Partnrs Research Analysts Lift Earnings Estimates for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Stock analysts at Leerink Partnrs upped their FY2026 earnings estimates for shares of Madrigal Pharmaceuticals in a research note issued to investors on Wednesday, August 7th. Leerink Partnrs analyst T. Smith now expects that the biopharmaceutical company will post earnings per share of $2.10 for the year, up from their prior estimate of $1.96. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($27.70) per share. Leerink Partnrs also issued estimates for Madrigal Pharmaceuticals’ FY2027 earnings at $22.76 EPS and FY2028 earnings at $38.44 EPS.

Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Madrigal Pharmaceuticals in a research report on Tuesday, July 23rd. HC Wainwright lowered their price target on shares of Madrigal Pharmaceuticals from $425.00 to $390.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. StockNews.com upgraded shares of Madrigal Pharmaceuticals to a “sell” rating in a research note on Friday, July 19th. Bank of America started coverage on shares of Madrigal Pharmaceuticals in a research note on Monday, April 22nd. They issued an “underperform” rating and a $150.00 target price for the company. Finally, JMP Securities upped their price target on Madrigal Pharmaceuticals from $381.00 to $385.00 and gave the stock a “market outperform” rating in a research report on Tuesday, July 16th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $343.83.

Madrigal Pharmaceuticals Stock Down 1.6 %

NASDAQ MDGL traded down $3.84 during midday trading on Friday, hitting $239.80. 156,464 shares of the company traded hands, compared to its average volume of 481,451. The company has a market cap of $5.11 billion, a PE ratio of -10.55 and a beta of -0.42. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.39 and a quick ratio of 9.39. Madrigal Pharmaceuticals has a 52 week low of $119.76 and a 52 week high of $299.98. The company’s 50-day simple moving average is $272.30 and its 200-day simple moving average is $245.85.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($7.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.55) by $0.45. The business had revenue of $14.64 million for the quarter, compared to analysts’ expectations of $4.25 million. The business’s quarterly revenue was up 146280.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($4.69) earnings per share.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in MDGL. First Horizon Advisors Inc. lifted its holdings in Madrigal Pharmaceuticals by 1,633.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 104 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 98 shares during the last quarter. Signaturefd LLC increased its holdings in shares of Madrigal Pharmaceuticals by 36.8% in the second quarter. Signaturefd LLC now owns 145 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 39 shares during the period. EntryPoint Capital LLC acquired a new position in Madrigal Pharmaceuticals during the 1st quarter worth approximately $41,000. UMB Bank n.a. purchased a new position in shares of Madrigal Pharmaceuticals in the 1st quarter valued at about $53,000. Finally, Quest Partners LLC boosted its stake in shares of Madrigal Pharmaceuticals by 5,225.0% during the 2nd quarter. Quest Partners LLC now owns 213 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 209 shares in the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Madrigal Pharmaceuticals

In related news, Director Fred B. Craves sold 22,489 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $212.88, for a total transaction of $4,787,458.32. Following the sale, the director now directly owns 413,362 shares of the company’s stock, valued at $87,996,502.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director Fred B. Craves sold 22,489 shares of the company’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $212.88, for a total transaction of $4,787,458.32. Following the completion of the sale, the director now owns 413,362 shares of the company’s stock, valued at $87,996,502.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Robert E. Waltermire sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $285.00, for a total value of $570,000.00. Following the transaction, the vice president now owns 5,500 shares in the company, valued at $1,567,500. The disclosure for this sale can be found here. Insiders have sold 27,425 shares of company stock worth $6,129,127 over the last 90 days. 23.92% of the stock is currently owned by company insiders.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.